(BHC) Bausch Health Companies - Ratings and Ratios

Bausch Health Companies Inc. (TO:BHC), a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a wide array of products. Their portfolio spans gastroenterology, hepatology, neurology, dermatology, generics, over-the-counter (OTC) products, aesthetic devices, and eye health, serving global markets.

The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. Salix focuses on gastrointestinal treatments, including notable products like Xifaxan. The International segment excels in aesthetic devices such as Thermage and markets branded, generic, and OTC products across various regions. Solta Medical is renowned for its Thermage systems in the aesthetic sector. The Diversified segment offers neurology products like Jublia and a range of generics and dermatology solutions. Bausch + Lomb, a leader in eye health, is known for products like LUMIFY and contact lenses.

Originally Valeant Pharmaceuticals International, Inc., the company rebranded as Bausch Health in July 2018. Headquartered in Laval, Canada, it continues to expand its global presence. For more information, visit their website at https://www.bauschhealth.com.

Ticker Symbol: BHC
Exchange: TO
Type: common stock
Country Origin: Canada
GICS Sub Industry: Pharmaceuticals

Based on current data, the 3-month forecast indicates potential volatility. Technically, with the last price below the SMA20, SMA50, and SMA200, a bearish trend may persist. However, the low forward P/E ratio suggests undervaluation, possibly indicating a rebound. The moderate ATR points to manageable volatility, signaling a consolidative phase with potential for sideways movement or a slight recovery.